Acute Respiratory Distress Syndrome - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 62 pages report, published by Global Markets Direct

Keywords : Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment

Report ThumbnailSeptember-2013
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. Acute Respiratory Distress Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Respiratory Distress Syndrome.
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2013 8
  • Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Products under Investigation by Universities/Institutes, H2 2013 11
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Discovery and Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 26
  • Assessment by Route of Administration, H2 2013 27
  • Assessment by Stage and Route of Administration, H2 2013 28
  • Assessment by Molecule Type, H2 2013 29
  • Assessment by Stage and Molecule Type, H2 2013 30
  • List of Tables
  • Number of Products Under Development for Acute Respiratory Distress Syndrome, H2 2013 8
  • Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Number of Products under Investigation by Universities/Institutes, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Products under Investigation by Universities/Institutes, H2 2013 17
  • Medinox, Inc., H2 2013 18
  • GlaxoSmithKline plc, H2 2013 19
  • Altor BioScience Corporation, H2 2013 20
  • Mondobiotech Holding AG, H2 2013 21
  • Ikaria Inc., H2 2013 22
  • Northern Therapeutics, Inc., H2 2013 23
  • Faron Pharmaceuticals, Ltd., H2 2013 24
  • Clarassance, Inc., H2 2013 25
  • Assessment by Monotherapy Products, H2 2013 26
  • Assessment by Stage and Route of Administration, H2 2013 28
  • Assessment by Stage and Molecule Type, H2 2013 30
  • Acute Respiratory Distress Syndrome Therapeutics - Drug Profile Updates 49
  • Acute Respiratory Distress Syndrome Therapeutics - Discontinued Products 53
  • Acute Respiratory Distress Syndrome Therapeutics - Dormant Products 54
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Acute Respiratory Distress Syndrome Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Acute Respiratory Distress Syndrome 8
  • Acute Respiratory Distress Syndrome Therapeutics under Development by Companies 10
  • Acute Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes 11
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Discovery and Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Acute Respiratory Distress Syndrome Therapeutics - Products under Development by Companies 16
  • Acute Respiratory Distress Syndrome Therapeutics - Products under Investigation by Universities/Institutes 17
  • Companies Involved in Acute Respiratory Distress Syndrome Therapeutics Development 18
  • Medinox, Inc. 18
  • GlaxoSmithKline plc 19
  • Altor BioScience Corporation 20
  • Mondobiotech Holding AG 21
  • Ikaria Inc. 22
  • Northern Therapeutics, Inc. 23
  • Faron Pharmaceuticals, Ltd. 24
  • Clarassance, Inc. 25
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment 26
  • Assessment by Monotherapy Products 26
  • Assessment by Route of Administration 27
  • Assessment by Molecule Type 29
  • Drug Profiles 31
  • dilmapimod - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • ALT-836 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • IK-6002 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • interferon beta-1a - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • interferon beta-1a - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • perfluorocarbon - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • CG-367 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • DasKloster-1000-04 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • DasKloster-014101 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • Drug for ARDS - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • CR-0014 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • Matrix Metalloprotease And Pro-Inflammatory Cytokine Inhibitors - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • Drug Targeting Leptin - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • Human Plasma Protein - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Acute Respiratory Distress Syndrome Therapeutics - Drug Profile Updates 49
  • Acute Respiratory Distress Syndrome Therapeutics - Discontinued Products 53
  • Acute Respiratory Distress Syndrome Therapeutics - Dormant Products 54
  • Acute Respiratory Distress Syndrome - Product Development Milestones 55
  • Featured News & Press Releases 55
  • Jun 03, 2013: CVie Therapeutics Submits Application For Phase II Clinical Study Of Istaroxime Injection In China 55
  • Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program 55
  • Sep 19, 2012: Unigene And Tarix Pharma Announce Completion Of Feasibility Study Of TXA127 56
  • May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 57
  • Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 57
  • Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 58
  • May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 58
  • Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 59
  • Jan 17, 2011: Rentschler And Faron Pharma Sign Manufacturing And Supply Agreement For Traumakine 59
  • Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study 60
  • Appendix 61
  • Methodology 61
  • Coverage 61
  • Secondary Research 61
  • Primary Research 61
  • Expert Panel Validation 61
  • Contact Us 62
  • Disclaimer 62

Please select a license type

Share

Related Products

Global Markets DirectAcute Respiratory Distress Syndrome - Pipeline Review, H2 2013Product ThumbnailAcute Respiratory Distress Syndrome - Pipeline Review, H2 2013, Industry ReportProduct #: 113292
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved